Lyra Therapeutics (LYRA)
(Delayed Data from NSDQ)
$0.32 USD
0.00 (1.41%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $0.32 0.00 (1.27%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Lyra Therapeutics, Inc. [LYRA]
Reports for Purchase
Showing records 1 - 10 ( 10 total )
Company: Lyra Therapeutics, Inc.
Industry: Medical - Drugs
LYR-210 Pivotal Miss In Surgically Naive CRS
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Lyra Therapeutics, Inc.
Industry: Medical - Drugs
LYR-210 Positioned For Phase 3 Differentiation; Topline Expected May ?24; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Lyra Therapeutics, Inc.
Industry: Medical - Drugs
Near-Term Sights on LYR-210 Pivotal ENLIGHTEN-1 Topline Expected 2Q24; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Lyra Therapeutics, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Lyra Therapeutics, Inc.
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Lyra Therapeutics, Inc.
Industry: Medical - Drugs
LYR-220 Further Establishes CRS Platform-Looking to Pivotal Topline 1H24; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Lyra Therapeutics, Inc.
Industry: Medical - Drugs
Boots on the Ground at ARS?23-KOL Perspectives on Announced LYR-220 Topline in Post-Surgical CRS; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Lyra Therapeutics, Inc.
Industry: Medical - Drugs
LYR-220 Topline Delivers For Phase 2 BEACON Study in Post-Surgical CRS; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Lyra Therapeutics, Inc.
Industry: Medical - Drugs
Drug-Eluting Mesh Implant for Durable Corticosteroid Delivery in CRS; Initiating With Buy Rating and $12 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CAUFIELD M
Company: Lyra Therapeutics, Inc.
Industry: Medical - Drugs
|